Literature DB >> 25972367

Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy.

S K Tedeschi1, E Massarotti2, H Guan2, A Fine2, B L Bermas2, K H Costenbader2.   

Abstract

Past studies have focused on aggregate lupus disease activity during pregnancy and have produced conflicting results. Our study evaluated lupus activity based on involvement of five specific organ systems during the six months prior to conception and during pregnancy. We assessed 147 pregnancies among 113 women followed at Brigham and Women's Lupus Center, 1990-2013. Organ-specific activity included hematologic disorder, nephritis, skin disease, arthritis, and serositis. We hypothesized that the presence of organ-specific activity six months prior to conception would increase the risk for that same type of activity during pregnancy. Our study population was 68% white; 100% had a positive ANA and 30% had a history of nephritis. Among women with organ-specific lupus activity during the six months before conception, the crude odds for the same type of activity during pregnancy was 7.7- to 32.5-fold higher compared to women without that type of activity immediately before conception. An adjusted logistic regression model also indicated significantly higher odds of organ-specific activity during pregnancy if that type of activity were present six months before conception. Approaching lupus based on specific organ systems may be a useful way for women and their physicians to consider the potential risk for disease activity during pregnancy.
© The Author(s) 2015.

Entities:  

Keywords:  Systemic lupus erythematosus; hematologic changes; nephritis; pregnancy

Mesh:

Substances:

Year:  2015        PMID: 25972367      PMCID: PMC4575819          DOI: 10.1177/0961203315586455

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

Review 1.  Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.

Authors:  Nathalie Costedoat-Chalumeau; Zahir Amoura; Du Le Thi Huong; Philippe Lechat; Jean-Charles Piette
Journal:  Autoimmun Rev       Date:  2004-12-14       Impact factor: 9.754

2.  Outcome of lupus pregnancy: a controlled study.

Authors:  P E Georgiou; E N Politi; P Katsimbri; V Sakka; A A Drosos
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

3.  Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies.

Authors:  J Cortés-Hernández; J Ordi-Ros; F Paredes; M Casellas; F Castillo; M Vilardell-Tarres
Journal:  Rheumatology (Oxford)       Date:  2002-06       Impact factor: 7.580

4.  Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia.

Authors:  A S Al Arfaj; N Khalil
Journal:  Lupus       Date:  2010-10-14       Impact factor: 2.911

5.  Hydroxychloroquine in lupus pregnancy.

Authors:  Megan E B Clowse; Laurence Magder; Frank Witter; Michelle Petri
Journal:  Arthritis Rheum       Date:  2006-11

6.  Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome.

Authors:  Enrico Imbasciati; Angela Tincani; Gina Gregorini; Andrea Doria; Gabriella Moroni; Gianfranca Cabiddu; Daniele Marcelli
Journal:  Nephrol Dial Transplant       Date:  2008-06-18       Impact factor: 5.992

Review 7.  The risk of pregnancy in patients with lupus nephritis.

Authors:  Gabriella Moroni; Claudio Ponticelli
Journal:  J Nephrol       Date:  2003 Mar-Apr       Impact factor: 3.902

8.  Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale.

Authors:  G Ruiz-Irastorza; M A Khamashta; C Gordon; M D Lockshin; K R Johns; L Sammaritano; G R V Hughes
Journal:  Arthritis Rheum       Date:  2004-02-15

9.  The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients.

Authors:  Chee-Seng Yee; Mohammed Akil; Munther Khamashta; Rupa Bessant; Rachael Kilding; Ian Giles; Vernon T Farewell; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2012-07-04       Impact factor: 7.580

10.  Anti-inflammatory and immunosuppressive drugs and reproduction.

Authors:  Monika Østensen; Munther Khamashta; Michael Lockshin; Ann Parke; Antonio Brucato; Howard Carp; Andrea Doria; Raj Rai; Pierluigi Meroni; Irene Cetin; Ronald Derksen; Ware Branch; Mario Motta; Caroline Gordon; Guillermo Ruiz-Irastorza; Arsenio Spinillo; Deborah Friedman; Rolando Cimaz; Andrew Czeizel; Jean Charles Piette; Ricard Cervera; Roger A Levy; Maurizio Clementi; Sara De Carolis; Michelle Petri; Yehuda Shoenfeld; David Faden; Guido Valesini; Angela Tincani
Journal:  Arthritis Res Ther       Date:  2006-05-11       Impact factor: 5.156

View more
  4 in total

1.  Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes.

Authors:  Sara K Tedeschi; Hongshu Guan; Alexander Fine; Karen H Costenbader; Bonnie Bermas
Journal:  Clin Rheumatol       Date:  2016-05-11       Impact factor: 2.980

Review 2.  The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy.

Authors:  Bonnie L Bermas; Melissa Tassinari; Megan Clowse; Eliza Chakravarty
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

3.  Pregnancy outcomes in women with childhood-onset and adult-onset systemic lupus erythematosus: a comparative study.

Authors:  Miguel Ángel Saavedra; Dafhne Miranda-Hernández; Antonio Sánchez; Sara Morales; Pilar Cruz-Domínguez; Gabriela Medina; Luis Javier Jara
Journal:  Rheumatol Int       Date:  2016-07-07       Impact factor: 2.631

4.  1,25-(OH)2D3/Vitamin D receptor alleviates systemic lupus erythematosus by downregulating Skp2 and upregulating p27.

Authors:  Dan Liu; Yu-Xuan Fang; Xia Wu; Wei Tan; Wei Zhou; Yu Zhang; Yan-Qing Liu; Guo-Qing Li
Journal:  Cell Commun Signal       Date:  2019-12-10       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.